Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Operating Income: 2011-2024

Historic Operating Income for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$302.6 million.

  • Ptc Therapeutics' Operating Income rose 105.53% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.9 million, marking a year-over-year increase of 677.47%. This contributed to the annual value of -$302.6 million for FY2024, which is 31.16% up from last year.
  • Per Ptc Therapeutics' latest filing, its Operating Income stood at -$302.6 million for FY2024, which was up 31.16% from -$439.5 million recorded in FY2023.
  • Ptc Therapeutics' 5-year Operating Income high stood at -$302.6 million for FY2024, and its period low was -$447.4 million during FY2022.
  • Its 3-year average for Operating Income is -$396.5 million, with a median of -$439.5 million in 2023.
  • In the last 5 years, Ptc Therapeutics' Operating Income tumbled by 79.04% in 2020 and then skyrocketed by 31.16% in 2024.
  • Over the past 5 years, Ptc Therapeutics' Operating Income (Yearly) stood at -$431.8 million in 2020, then grew by 13.28% to -$374.4 million in 2021, then fell by 19.49% to -$447.4 million in 2022, then rose by 1.77% to -$439.5 million in 2023, then surged by 31.16% to -$302.6 million in 2024.